Liquid Biopsy in Lung Cancer

Samsung Medical Center111 enrolled

Overview

The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.

The peripheral blood and tumor tissue samples are collected from the participants.CTC and ctDNA are analyzed from the blood samples.

Study Type

OBSERVATIONAL

Enrollment

111

Conditions

Lung Cancer (Diagnosis)Circulating Tumor Cell

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with histology-proven lung cancer or a clinical suspicion of lung cancer * Age \>=18, \< 80 years * No previous history of cancer treatment within 5 years * Patients who agree to participate Exclusion Criteria: * Patients who have been diagnosed with malignancy within 5 years * Patients with previous history of lung cancer * Patients who have uncontrolled coagulopathy

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Diagnostic sensitivity of combined CTC and ctDNA

To compared the sensitivity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer

Time frame: 1 year

Secondary Outcomes

Diagnostic accuracy of combined CTC and ctDNA

To compared the accuracy of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer

Time frame: 1 year

Diagnostic specificity of CTC and ctDNA

To compared the specificity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.